Table 2.
The patients’ clinical data in all included articles.
| First author of study and [Ref.] | Follow-up (month) | PCa Population | Primary treatment | Age (years) | PSA level (ng/ml) | Outcome | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Total | Yes FH | No FH | Total | Yes FH | No FH | |||||
| Hanus et al. [24] | NR | Localized PCa | EBRT | 68 | 66 | 68 | 16.7 | 16.9 | 16.6 | BCR |
| Ray et al. [25] | 48 | Localized PCa | EBRT ± NADT | NR | 68 | 68.4 | NR | 8.1 | 7.7 | BCR |
| Lee et al. [26] | 91 | Localized PCa | RP | NR | 62 | 64 | NR | 7.2 | 7.8 | BCR |
| Spangler et al. [27] | 21 | Localized PCa | RP | NR | NR | NR | NR | NR | NR | BCR |
| Roehl et al. [28] | 47 | Localized PCa | RP | NR |
63 (Sibling pairs) 61 (Hereditary) 60 (High density family member) |
61 | NR |
6.5 (Sibling pairs) 5.9 (Hereditary) 6.1 (High density family member) |
5.9 | BCR |
| Kupelian et al. [29] | 65 | Localized PCa |
RP (n = 1971) RT (n = 2141) |
≤65 (n = 2059) >65 (n = 2053) |
≤65 (n = 358) >65 (n = 301) |
≤65 (n = 1701) >65 (n = 1752) |
≤4 (n = 399) >4 to ≤10 (n = 2427) >10 to ≤20 (n = 869) >20 (n = 417) |
≤4 (n = 66) >4 to ≤10 (n = 406) >10 to ≤20 (n = 131) >20 (n = 56) |
≤4 (n = 333) >4 to ≤10 (n = 2021) >10 to ≤20 (n = 738) >20 (n = 361) |
BCR |
| Peters et al. [30] | 60 | Localized PCa | LDR ± ADT | NR | 65 | 67 | NR |
<10 (n = 142) 10 to 20 (n = 37) >20 (n = 14) |
<10 (n = 1132) 10 to 20 (n = 286) >20 (n = 132) |
BCR |
| Bagshaw et al. [31] | 71 | Localized PCa | IMRT | 68.2 | 67.4 | 68.5 | 6.3 | 6 | 6.4 |
BCR CSS OS |
| Westerman et al. [13] | 119 | Localized PCa | RP | 63 | 62 | 64 | 6.1 | 6 | 6.2 |
BCR CSS OS |
| Thalgott et al. [32] | 74.5 | Localized PCa | RP | 63.9 | 63.0 (FPC) | 65.9 (SPC) | 11.8 | 11.5 (FPC) | 11.1 (SPC) |
BCR CSS (FPC/SPC) |
| Lee et al. [6] | 40.5 | Localized PCa | RP | NR | 62.7 | 65.6 | 7.4 | 7.75 | 7.38 | BCR |
PCa prostate cancer, FH family history, EBRT external beam radiotherapy, ADT androgen deprivation therapy, NADT neoadjuvant ADT, RP radical prostatectomy, RT radiation therapy, LDR low-dose radiotherapy, FPC familial prostate cancer, SPC sporadic prostate cancer, BCR biochemical recurrence, CSS cancer-specific survival, OS overall survival.